China Biopharmaceutical Industry Report, 2004
  • Oct/2004
  • Hard Copy
  • USD $900
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $1,000
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,500
  • Hard Copy + Single User License
  • USD $1,100


1.Definition, classification and characteristics of the biopharmaceutical industry
1.1 Definition and classification
1.2 Index analysis of biomedicine
1.2.1 High technology
1.2.2 Large investment
1.2.3 Long periodicity
1.2.4 High risks
1.2.5 High profitability
1.2.6 Obstacles to enter
1.2.7 Growth of the industry
1.3 Related industries’ development
1.3.1 Sector of biomedical engineering 
1.3.2 Sector of biomedical materials 
1.3.3 Medical treatment packaging industry
1.3.4 Biochip industry

2.Development of the international biopharmaceutical industry
2.1 Global biopharmaceutical market scale
2.1.1 Characteristics of the overseas biopharmaceutical industry’s development
2.1.2 General scale of the global biopharmaceutical industry
2.2 Listed biotech companies in the world
2.2.1 Operation analysis
2.2.2 Major biopharmaceutical companies’ operation status in 2003.
2.3 Status of major biopharmaceutical markets in the world
2.3.1 General situation
2.3.2 Global gene engineering industry
2.3.3 Analysis and forecast of the therapeutic albumen market, 2002-2010
2.4 Trends of global biopharmaceutical industry
2.4.1 Forecasts 
2.4.2 The best-selling biomedicine products 
2.4.3 Medicines that are under development and will soon be put into production 

3.Operation status of the biopharmaceutical industry in major regions
3.1 The United States 
3.1.1 American biotechnology saw a rise in 2003
3.1.2 Biotech companies become the investment focus
3.2 Japanese biopharmaceutical industry
3.2.1 Introduction
3.2.2 Long-term scale of Japanese biotech industry
3.2.3 Achievements of Japan’s protein structure research
3.3 European biopharmaceutical industry
3.3.1 Market share of biomedicine products
3.3.2 Development characteristics of European biotech enterprises 
3.4 German biopharmaceutical industry
3.5 Denmark biopharmaceutical industry

4.Analysis of China's pharmaceutical industry in 2003
4.1 General operation status of the pharmaceutical industry
4.1.1 Definition and classification of the industry
4.1.2 Summary of the operation status of China's pharmaceutical industry in 2003
4.2 Changes in the number of pharmaceutical enterprises
4.2.1 Changes in the number of pharmaceutical enterprises and the situation of its sub-industries. 2001-2003, by State Statistical Bureau
4.2.2 Changes regarding the number of pharmaceutical enterprises from 2001 to 2003
4.2.3 Changes regarding the number of pharmaceutical subsidiary enterprises, monitored by SETC
4.3.Analysis on the output value, profits, sales revenue growth of the pharmaceutical industry
4.3.1 Analysis on the general situation of the pharmaceutical industry, 2001-2003
4.3.2 Analysis on the pharmaceutical sub-industries., 2001-2003
4.3.3 Analysis on the profits and losses of pharmaceutical industry and its sub-industries, 2001-2003

5.China's biopharmaceutical industry
5.1 Operation status of China's biopharmaceutical industry, 2003
5.1.1 Comparison analysis of China's biopharmaceutical industry, 2001-2003 
5.1.2 Operation status of China's biopharmaceutical industry, 2003
5.1.3 Operation status of China's biopharmaceutical industry, 2002
5.1.4 Operation status of China's biopharmaceutical industry, 2001
5.2 Operation status of different types of biopharmaceutical enterprises
5.2.1 Enterprises in different scales
5.2.2 Enterprises in different economic types

6.Regional Analysis on the biopharmaceutical industry
6.1 Overall comparison 
6.1.1 Regional output ranking according to current production value, 2003
6.1.2 Regional output ranking by according to current production value, 2002
6.1.3 Comparison analysis on the performances of different regions in 2003
6.2 Operation status of the biopharmaceutical industry in Hubei, 2003
6.3 Operation status of the biopharmaceutical industry in Zhejiang, 2003
6.4 Operation status of the biopharmaceutical industry in Shandong, 2003
6.5 Operation status of the biopharmaceutical industry in Shanghai, 2003
6.6 Operation status of the biopharmaceutical industry in Guangdong, 2003
6.7 Operation status of the biopharmaceutical industry in Beijing, 2003
6.8 Operation status of biopharmaceutical industry in Tianjin, 2003
6.9 Operation status of biopharmaceutical industry in Jiangsu, 2003

7.Market segmentation of China's biopharmaceutical industry
7.1 Analysis of the major products sales 
7.1.1 Sales of major biomedical drugs 
7.1.2 R&D of the gene engineering medicine
7.2 Production and sales of domestic interferon market
7.2.1 Major interferon types
7.2.2 Big market space
7.2.3 Competition is getting fiercer 
7.2.4 Time is needed for growing 
7.2.5 Current listed interferon companies
7.3 Vaccine market
7.3.1 Domestic vaccine market contains great commercial opportunities 
7.3.2 Current status of domestic vaccine manufacturers
7.3.3 Influenza vaccine market
7.3.4 Hepatitis B virus vaccine market
7.4 Other market segments
7.4.1 Human blood albumin
7.4.2 Erythropoietin
7.4.3 Interleukin
7.4.4 Colony stimulating factor
7.4.5 Human growth hormone
7.4.6 Insulin

8.Biomedicine imports and exports
8.1 Major products imported, 2003
8.2 Major products exported, 2003
8.2.1 Total exports
8.2.2 Major export destinations, export quantity and value

9.Operation status of China's leading biopharmaceutical enterprises
9.1 Ranking
9.1.1 Sales revenue and profits of the top 10 enterprises (ranking by sales revenue), 2003 
9.1.2 Top 200 biopharmaceutical enterprises (in terms of sales revenue), by State Statistical Bureau 2002
9.1.3 Top 200 biopharmaceutical enterprises (in terms of profits), by State Statistical Bureau
9.1.4 Top 100 biopharmaceutical enterprises in terms of sales revenue and profits, by SETC
9.2 Operation status of the listed biopharmaceutical companies
9.3 Case study: Beijing TIANTAN Biological Products Co,. Ltd
9.3.1 General information
9.3.2 Analysis on its operations in 2003

10.Recommendations for biopharmaceutical investment
10.1 Blank points of the biopharmaceutical investment
10.2 Biopharmaceutical investment and financing strategy
10.2.1 Investment strategy in the United States 
10.2.2 Types of biopharmaceutical investment in China
10.2.3 Venture capital investment applies in biopharmaceutical industry
10.2.4 Advance and retreat principle of biopharmaceutical investmen
General market scale of biotech industry, 1994-2003 
Increasing trends of pharmaceutical industry's profitability, by month in 2003
Enterprise number of each China's pharmaceutical sub-industry
Proportion of pharmaceutical sub-industries by production value
Sales revenue of the pharmaceutical industry and its sub-industries
Profitability of the pharmaceutical industry and its sub- industries 
Production value, sales revenue and profit growth of China's biopharmaceutical industry, 2000-2003
Increase rate of insulin market
Major biopharmaceutical products' import quantity and value 
Characteristics of the biopharmaceutical industry
Ranking of the global top 500 pharmaceutical and biotech companies
Comparison of biotech industry between 2001 and 2002
Biopharmaceutical products with higher market shares
Medicines that will be put into production in the next three years 
Basic operational status of China's pharmaceutical industry, 2003
Sales revenue and profits of the top 10 biopharmaceutical enterprises, 2003
Selected listed biopharmaceutical companies
Benefit status of major pharmaceutical sub-industries, 2003
Important agreements signed by biotech and pharmaceutical companies in 2003
Major biopharmaceutical products' export quantity and value
Major export destinations, quantity, value and average price of vaccines for human medicine
Major export destinations, quantity, value and average price of vaccines for animal medicine

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号